/GELS
GELS Stock - Gelteq Limited Ordinary Shares
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$0.90+4.37%
+$0.04 (+4.37%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.1
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GELS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.89 – $0.91
TARGET (TP)$1.03
STOP LOSS$0.83
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.87
52W High$4.11
52W Low$0.77
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $165,645 | N/A | $79,843 | $147,536 | N/A |
| Gross Profit | $165,645 | N/A | $30,918 | $52,662 | N/A |
| Gross Margin | 100.0% | N/A | 38.7% | 35.7% | N/A |
| Operating Income | $-5,495,527 | $-2,945,975 | $-3,102,151 | $-3,193,257 | $-647,624 |
| Net Income | $-6,645,453 | $-3,546,195 | $-3,506,220 | $-3,368,891 | $-648,921 |
| Net Margin | -4011.9% | N/A | -4391.4% | -2283.4% | N/A |
| EPS | $0.00 | $0.00 | $-0.37 | $-0.36 | $-0.07 |
Company Overview
Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals. It offers white label gel-based delivery solutions for prescription drugs, over-the-counter products, nutraceuticals and sports, pet care, and other products. The company was incorporated in 2017 and is headquartered in Caulfield, Australia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
GELSLoading earnings data...
Latest News
Gelteq Partners With Hong Kong Flag Football Program To Integrate Hydration And Performance Formulations Into Training And Competition Programs
📈 PositiveBenzinga•Dec 16, 2025, 02:09 PM
Gelteq Signs 3-Year China Distribution Deal With Mana To Expand Nutritional Product Portfolio; Expects To Derive A Minimum Revenue Of ~$1.3M During The Term Of The Agreement
📈 PositiveBenzinga•Dec 9, 2025, 02:16 PM
Gelteq Announces Preclinical Findings Demonstrative Oral Delivery Of Oil-Soluble And Poorly Soluble Drugs Using Co's Gel-Based Platform
📈 PositiveBenzinga•Dec 5, 2025, 03:31 PM•Also: , ,
Gelteq shares are trading higher after the company announced preclinical results for its proprietary gel formulation.
📈 PositiveBenzinga•Nov 24, 2025, 02:10 PM
Gelteq Announces Preclinical Results Showing That Its Proprietary Gel-Based Oral Delivery Formulation Significantly Improves The Bioavailability Of An Antihistamine Compared To A Leading Existing Product
📈 PositiveBenzinga•Nov 24, 2025, 01:34 PM
Gelteq shares are trading higher after the company announced commencement of preclinical trial for poorly soluble drugs.
📈 PositiveBenzinga•Oct 23, 2025, 03:41 PM
Gelteq Announces Start Of A Preclinical Animal Trial With Monash University To Evaluate Its Proprietary Gel-Based Oral Delivery Technology For Oily And Poorly Soluble Drugs
📈 PositiveBenzinga•Oct 23, 2025, 01:06 PM
Gelteq Signs Product Development, Profit Share Agreement With Melbourne Health To Develop New Products Incorporating High-amylose Maize Starch Butyrylated
📈 PositiveBenzinga•Oct 9, 2025, 12:11 PM
Gelteq Technology Powers U.S. Launch Of Healthy Extracts' Nutraceuticals, Marking Transition From R&D To Commercialization
📈 PositiveBenzinga•Sep 12, 2025, 11:33 AM•Also:
Gelteq shares are trading higher after the company announced plans to commence a preclinical bioequivalence study in September 2025 to evaluate its novel gel-based formulation of a widely used antihistamine for allergy treatment.
📈 PositiveBenzinga•Sep 5, 2025, 03:31 PM
Gelteq To Begin Preclinical Study Of Gel-Based Antihistamine Formulation In September 2025, Aiming For FDA Approval Via 505(b)(2) Regulatory Pathway
📈 PositiveBenzinga•Sep 5, 2025, 03:29 PM
Gelteq And Healthy Extracts Launch Hydrate EZ And Mynus Sugar Gel-Packs With Innovative No-Mix Delivery Technology
📈 PositiveBenzinga•Sep 4, 2025, 12:43 PM•Also:
Frequently Asked Questions about GELS
What is GELS's current stock price?
Gelteq Limited Ordinary Shares (GELS) is currently trading at $0.90 per share. The stock has moved +4.37% today.
What is the analyst price target for GELS?
No analyst price targets are currently available for this stock.
What sector is Gelteq Limited Ordinary Shares in?
Gelteq Limited Ordinary Shares operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is GELS's market cap?
Gelteq Limited Ordinary Shares has a market capitalization of $0.01 billion, making it a small-cap company.
Does GELS pay dividends?
No, Gelteq Limited Ordinary Shares does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAYTU
Aytu BioPharma, Inc.
$2.55
Mkt Cap: $0.0B
BFRG
Bullfrog AI Holdings, Inc. Common Stock
$1.13
Mkt Cap: $0.0B
BFRI
Biofrontera Inc.
$0.77
Mkt Cap: $0.0B
BGLC
BioNexus Gene Lab Corp.
$4.23
Mkt Cap: $0.0B
COCP
Cocrystal Pharma, Inc.
$0.99
Mkt Cap: $0.0B
EVGN
Evogene Ltd.
$1.02
Mkt Cap: $0.0B
IMNN
Imunon, Inc.
$3.75
Mkt Cap: $0.0B
IMRN
Immuron Limited
$0.94
Mkt Cap: $0.0B
PRPH
ProPhase Labs, Inc.
$0.09
Mkt Cap: $0.0B
SBFM
Sunshine Biopharma, Inc.
$1.39
Mkt Cap: $0.0B
Explore stocks similar to GELS for comparison